Wed, March 5, 2025
Tue, March 4, 2025
[ Tue, Mar 04th ]: MSN
What Drives Nvidia's Growth?

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. -rest-of-the-branded-pharmaceuticals-stocks.html
  Print publication without navigation Published in Stocks and Investing on by MSN
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
  As the Q4 earnings season comes to a close, it's time to take stock of this quarter's best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers.

The article from MSN Money discusses the performance of branded pharmaceutical stocks during the fourth quarter, focusing particularly on Corcept Therapeutics (NASDAQ: CORT). Corcept Therapeutics reported a significant earnings beat, with earnings per share (EPS) of $0.28 against the expected $0.22, and revenue of $123.6 million compared to the anticipated $119.11 million. This performance was driven by strong sales of their Cushing's syndrome treatment, Korlym. The article also mentions other branded pharmaceutical companies like Jazz Pharmaceuticals, which also beat earnings expectations, and contrasts this with companies like Intra-Cellular Therapies, which missed their earnings targets. The overall narrative highlights the mixed results within the sector, with some companies benefiting from robust product sales while others faced challenges.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/savingandinvesting/q4-earnings-outperformers-corcept-nasdaq-cort-and-the-rest-of-the-branded-pharmaceuticals-stocks/ar-AA1AdkV5 ]